Corundum Group, Inc. Bristol Myers Squibb CO Transaction History

Corundum Group, Inc.

$224 Million
Q2 2025

A detailed history of Corundum Group, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Corundum Group, Inc. holds 25,478 shares of BMY stock, worth $1.16 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares

25,478

Previous 25,338 0.55%

Holding current value

$1.16 Million

Previous $1.55 Million 23.69%

% of portfolio

0.53%

Previous 0.75%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 21, 2025	BUY	$44.12 - $59.6 $6,176 - $8,344	140 Added 0.55%	25,478 $1.18 Million
Q1 2025 Apr 23, 2025	SELL	$53.9 - $63.11 $980,764 - $1.15 Million	-18,196 Reduced 41.8%	25,338 $1.55 Million
Q4 2024 Jan 16, 2025	BUY	$51.92 - $59.94 $913,584 - $1.05 Million	17,596 Added 67.84%	43,534 $2.46 Million
Q3 2024 Oct 18, 2024	SELL	$39.66 - $51.75 $89,512 - $116,799	-2,257 Reduced 8.0%	25,938 $1.34 Million
Q2 2024 Jul 17, 2024	BUY	$40.25 - $52.99 $712,143 - $937,552	17,693 Added 168.47%	28,195 $1.17 Million
Q1 2024 Apr 15, 2024	BUY	$47.98 - $54.4 $291,910 - $330,969	6,084 Added 137.71%	10,502 $569,000
Q4 2023 Jan 23, 2024	SELL	$48.48 - $57.85 $168,225 - $200,739	-3,470 Reduced 43.99%	4,418 $226,000
Q3 2023 Oct 17, 2023	SELL	$57.89 - $64.73 $55,169 - $61,687	-953 Reduced 10.78%	7,888 $457,000
Q2 2023 Jul 21, 2023	SELL	$63.71 - $70.74 $415,771 - $461,649	-6,526 Reduced 42.47%	8,841 $565,000
Q1 2023 Apr 24, 2023	BUY	$65.71 - $74.53 $500,513 - $567,695	7,617 Added 98.28%	15,367 $1.07 Million
Q4 2022 Jan 12, 2023	BUY	$68.48 - $81.09 $26,501 - $31,381	387 Added 5.26%	7,750 $558,000
Q3 2022 Oct 18, 2022	BUY	$0.13 - $76.84 $54 - $32,503	423 Added 6.1%	7,363 $523,000
Q2 2022 Jul 25, 2022	SELL	$72.62 - $79.98 $102,612 - $113,011	-1,413 Reduced 16.92%	6,940 $534,000
Q1 2022 May 02, 2022	BUY	$61.48 - $73.72 $15,308 - $18,356	249 Added 3.07%	8,353 $610,000
Q4 2021 Feb 07, 2022	BUY	$53.63 - $62.52 $46,443 - $54,142	866 Added 11.96%	8,104 $505,000
Q3 2021 Nov 02, 2021	BUY	$59.17 - $69.31 $50,945 - $59,675	861 Added 13.5%	7,238 $428,000
Q2 2021 Aug 02, 2021	BUY	$61.91 - $67.42 $60,733 - $66,139	981 Added 18.18%	6,377 $426,000
Q1 2021 May 10, 2021	BUY	$59.34 - $66.74 $18,929 - $21,290	319 Added 6.28%	5,396 $341,000
Q4 2020 Feb 03, 2021	BUY	$57.74 - $65.43 $10,970 - $12,431	190 Added 3.89%	5,077 $315,000
Q3 2020 Nov 12, 2020	BUY	$57.43 - $63.64 $280,660 - $311,008	4,887 New	4,887 $294,000
Q3 2020 Nov 10, 2020	SELL	$57.43 - $63.64 $254,300 - $281,797	-4,428 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$54.82 - $64.09 $242,742 - $283,790	4,428 New	4,428 $260,000
Q2 2020 Aug 06, 2020	SELL	$54.82 - $64.09 $263,190 - $307,696	-4,801 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$46.4 - $67.43 $222,766 - $323,731	4,801 New	4,801 $268,000
Q1 2020 May 06, 2020	SELL	$46.4 - $67.43 $247,822 - $360,143	-5,341 Closed	0 $0
Q4 2019 Jan 28, 2020	BUY	$49.21 - $64.19 $9,054 - $11,810	184 Added 3.57%	5,341 $343,000
Q3 2019 Nov 01, 2019	BUY	$42.77 - $50.71 $220,564 - $261,511	5,157 New	5,157 $261,000
Q3 2019 Oct 30, 2019	SELL	$42.77 - $50.71 $220,693 - $261,663	-5,160 Closed	0 $0
Q2 2019 Aug 02, 2019	BUY	$44.62 - $49.34 $1,695 - $1,874	38 Added 0.74%	5,160 $234,000
Q1 2019 May 08, 2019	BUY	$45.12 - $53.8 $231,104 - $275,563	5,122 New	5,122 $244,000
Q4 2018 Feb 19, 2019	SELL	$48.76 - $63.23 $198,404 - $257,282	-4,069 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$50.53 - $62.98 $9,550 - $11,903	189 Added 4.87%	4,069 $225,000
Q1 2018 May 09, 2018	SELL	$59.92 - $68.98 $47,816 - $55,046	-798 Reduced 17.06%	3,880 $245,000
Q4 2017 Feb 13, 2018	BUY	$59.94 - $65.35 $239 - $261	4 Added 0.09%	4,678 $287,000
Q3 2017 Nov 03, 2017	BUY	$55.23 - $63.74 $258,145 - $297,920	4,674	4,674 $298,000

Others Institutions Holding BMY

# of Institutions

2,691

Shares Held

1.58B

Call Options Held

25.9M

Put Options Held

24.1M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $96.4B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Corundum Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Corundum Group, Inc. with notifications on news.

Account

Corundum Group, Inc. Bristol Myers Squibb CO Transaction History